Related Experiment Video
Updated: Jun 8, 2026
05:33
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Pharmacokinetic evaluation of idebenone
Claudia Becker1, Katharine Bray-French, Juergen Drewe
1Basel Pharmacoepidemiology Unit, University Hospital Basel, Switzerland.
Expert Opinion on Drug Metabolism & Toxicology
|October 20, 2010
Summary
Idebenone, an antioxidant and ATP facilitator, is being studied for mitochondrial diseases. Advanced analytical methods now allow detailed tracking of idebenone and its metabolites, aiding therapeutic potential evaluation.
Area of Science:
- Mitochondrial medicine
- Pharmacology
- Drug metabolism
Background:
- Idebenone functions as an electron carrier in mitochondrial ATP production.
- It possesses antioxidant properties, protecting cellular structures from oxidative damage.
- Currently approved for Friedreich's ataxia, idebenone is under investigation for other neuromuscular and mitochondrial disorders.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, and clinical efficacy/safety of idebenone and its metabolites.
- To provide an update on ongoing and completed clinical trials involving idebenone.
Main Methods:
- Review of existing literature on idebenone's pharmacology and pharmacokinetics.
- Summary of clinical trial data regarding efficacy and safety.
- Discussion of advanced analytical techniques for metabolite quantification.
Main Results:
- Idebenone undergoes rapid metabolism via CYP enzymes and conjugation (glucuronidation, sulfatation).
- New analytical methods enable separate quantification of idebenone and its primary metabolite, QS10.
- Dose-proportional pharmacokinetics observed up to 2250 mg/day in healthy subjects.
Conclusions:
- Idebenone is rapidly metabolized through first-pass metabolism.
- Advanced analytical techniques facilitate pharmacokinetic/pharmacodynamic relationship studies.
- Idebenone demonstrated safety and tolerability at doses up to 2250 mg/day in clinical studies.
Related Concept Videos
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:30Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:17Kinetics of Drug Elimination
Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...